Biosimilars in rheumatology: The wind of change

Annals of the Rheumatic Diseases

Volumn 72, Issue 3, 2013, Pages 315-318

  Schneider, Christian K ^a,b  

^a Danish Health and Medicines Authority   (Denmark)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BELIMUMAB; BIOSIMILAR AGENT; CANAKINUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HUMAN GROWTH HORMONE; INFLIXIMAB; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RILONACEPT; RILONACEPT REGENERON; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

CLINICAL DECISION MAKING; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

BIOSIMILAR PHARMACEUTICALS; HUMANS; RHEUMATOLOGY; THERAPEUTIC EQUIVALENCY;

EID: 84873679430     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202941     Document Type: Review

References (25)

1. European Medicines Agency. Guideline on simila biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues EMA/ CHMP/BMWP/403543/2010. 2012. http://www.emaeuropa.eu/docs/en-GB/document- library/Scientific-guideline/2012/06/WC500128686.pdf (accessed 6 Jan 2013).
2. European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use: April 2012. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Report/2012/04/ WC500125365.pdf (accessed 6 Jan 2013).
3. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 2012; 7 (Suppl 1): S57-67.
4. Shaw BE, Confer DL, Hwang WY et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011; 96: 942-7.
5. Barosi G, Bosi A, Abbracchio M.P., et al Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011; 96: 937-42.
6. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19: 411-19.
7. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology-"O Brave New World". Nat Rev Rheumatol 2012; 8: 430-6.
8. Dörner T., Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013; 72: 322-8.
9. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products) EMA/837805/2011. 2012. http://www.ema.europa.eu/docs/enGB/documentlibrary/Medicine-QA/2009/12/ WC500020062.pdf (accessed 6 Jan 2013).
10. Schiestl M, Stangler T, Torella C., et al Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29: 310-12.
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process Q5E. 2004. http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Quality/Q5E/Step4/Q5E-Guideline.pdf (accessed 6 Jan 2013).
12. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22: 1383-91.
13. Schneider CK, Schäffner-Dallmann G. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe. Nat Rev Drug Discov 2008; 7: 893-9.
14. http://www.ema.europa.eu > "Find Medicine" > [type name] > "Assessment history" > "[name]: EPAR - Procedural steps taken before authorisation". (accessed 6 Jan 2013).
15. http://www.ema.europa.eu > "Find Medicine" > [name] > "Assessment history" > "[name]: EPAR - steps taken and scientific information after authorisation"; for products licensed before the deadline also refer to "[name]: EPAR - Steps taken after authorisation when a cutoff date has been used" (accessed 6 Jan 2013).
16. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26: 985-90.
17. Weise M, Bielsky MC, De Smet K, et al Biosimilars - why terminology matters. Nat Biotechnol 2011; 29: 690-3.
18. Brockmeyer C, Seidl A. Binocrit: Assessment of quality, safety and efficacy of biopharmaceuticals. EJHP Practice 2009; 15: 38-44.
19. Waller CF. Critical appraisal of biosimilar filgrastim (Nivestim") for febrile and chemotherapy-induced neutropenia. Biosimilars 2012; 2: 1-11.
20. Schellekens H. Biosimilar therapeutics - what do we need to consider? NDT Plus 2009; 2(SUPPL. 1): i27-36.
21. Schneider CK, Borg JJ, Ehmann F et al. A response from the scientific and regulatory perspective in support of the EU biosimilar framework. Nat Biotechnol 2012; 30: 745-8.
22. Annex of Regulation (EC) 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Off J Eur Union 2004; L 136: 1-33.
23. European Medicines Agency. EPAR - Procedural steps taken before authorisation. www.ema.europa.eu (accessed 6 Jan 2013).
24. Weise M, Bielsky MC, De Smet K, et al Biosimilars: what clinicians should know. Blood 2012; 120: 5111-7.
25. Schneider CK, Vleminckx C, Gravanis I., et al Setting the stage for biosimilar monoclonal antibodies. Nat Biotechnol 2012; 30: 1179-85.